Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Quality cancer care is a team effort. In addition, patients' symptoms change over the course of treatment. As such, the Edmonton Symptom Assessment System (ESAS) is a simple tool designed to quickly monitor symptom change. Here, we present the results from a two-phase study aimed at validating the Arabic version of the ESAS (ESAS-A). Phase one involved the creation of two versions of the ESAS with both reverse and forward translations by bilingual, native Arabic speakers as well as evaluation by an expert panel. The reconciled version was then administered to 20 patients as a pilot from which to create the final version, which was then used with 244 patients. Phase two for the ESAS-involved an ESAS-based validation of 244 adults aged 18 years and older who were diagnosed with advanced cancer; then, further validation was completed in conjunction with two other symptom survey tools, the EORTC-Pal 15 and the HADS. The ESAS-A items possessed good internal consistency with an average Cronbach's alpha of 0.84, ranging from 0.82 to 0.85. Moreover, the results of ESAS-A showed good agreement with those of EORTC QLQ- 15 PAL (r = 0.36 to 0.69) and HADS (r = 0.60 and 0.57) regarding anxiety and depression. We found the ESAS-A to be responsive to symptom change and a median time to completion of 3.73 min. The results of our study demonstrate that the ESAS-A is a reliable, valid, and feasible tool for the purposes of monitoring symptom change over the course of cancer treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915286PMC
http://dx.doi.org/10.3390/ijerph20032571DOI Listing

Publication Analysis

Top Keywords

symptom change
12
arabic version
8
edmonton symptom
8
symptom assessment
8
assessment system
8
change course
8
symptom
6
esas-a
5
validation arabic
4
version
4

Similar Publications

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity.

View Article and Find Full Text PDF

The human auditory system must distinguish relevant sounds from noise. Severe hearing loss can be treated with cochlear implants (CIs), but how the brain adapts to electrical hearing remains unclear. This study examined adaptation to unilateral CI use in the first and seventh months after CI activation using speech comprehension measures and electroencephalography recordings, both during passive listening and an active spatial listening task.

View Article and Find Full Text PDF

Background: Ovarian cancer remains the most lethal gynecological cancer, with fewer than 50% of patients surviving more than five years after diagnosis. This study aimed to analyze the global epidemiological trends of ovarian cancer from 1990 to 2021 and also project its prevalence to 2050, providing insights into these evolving patterns and helping health policymakers use healthcare resources more effectively.

Methods: This study comprehensively analyzes the original data related to ovarian cancer from the GBD 2021 database, employing a variety of methods including descriptive analysis, correlation analysis, age-period-cohort (APC) analysis, decomposition analysis, predictive analysis, frontier analysis, and health inequality analysis.

View Article and Find Full Text PDF

Background: The river ecosystems provide habitats and source of water for a number of species including humans. The uncontrolled accumulation of pollutants in the aquatic environment enhances the development of antibiotic-resistant bacteria and genes.

Methods: Water samples were collected seasonally from different sites of Gomti and Ganga River.

View Article and Find Full Text PDF

Commentary: towards a name change of schizophrenia: positive and negative symptoms disorder (PND).

Eur Arch Psychiatry Clin Neurosci

September 2025

Laboratory of Neuroscience - LIM 27, Institute of Psychiatry, University of Sao Paulo, Rua Doutor Ovidio Pires de Campos, 785, 4º andar, sala 4N60, Sao Paulo, CEP 05403-903, Brazil.

View Article and Find Full Text PDF